{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:18:40Z","timestamp":1773364720644,"version":"3.50.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Spinal muscular atrophy (SMA) is a genetic disorder caused by genetic defect of <jats:italic toggle=\"yes\">SMN1<\/jats:italic> gene. SMA was an untreatable disease until 2016, when Nusinersen an antisense oligonucleotide therapy was approved for treatment. We report the effect of Nusinersen in a late onset SMA for 14\u200amonths.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 13-year-old boy who was diagnosed as SMA with progressive proximal limb weakness was treated with intrathecal injection of Nusinersen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient had progressive proximal limb weakness after 2\u200ayears of age. The patient had elevated creatine kinase level and shoed neurogenic changes in the needle electromyography study. After genetic analysis, homozygous deletion in Exon 7 and 8 of SMN1 protein was found and he was diagnosed as late onset SMA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Intrathecal Nusinersen was administered per protocol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 14\u200amonths of treatment, the patient showed significant clinical improvement in the revised Hammersmith functional rating scale and 6-minute walk test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Although there is limited data on the effect of Nusinersen in late onset SMA patients, our case adds on the effectiveness even in late onset SMA. More studies are needed to consolidate the effects and adverse events of Nusinersen in late onset SMA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024236","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:39:12Z","timestamp":1610584752000},"page":"e24236","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Effect of Nusinersen in a late onset spinal muscular atrophy patient for 14\u200amonths"],"prefix":"10.1097","volume":"100","author":[{"given":"Jin-Mo","family":"Park","sequence":"first","affiliation":[{"name":"Department of Neurology, Dongguk University College of Medicine, Dongguk University Gyeongju Hospital, Gyeongju"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Sun","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Kyungpook National University Chilgok hospital, School of Medicine, Kyungpook National University, Daegu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghwi","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Ulsan University Hospital, University of Ulsan College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5506-9206","authenticated-orcid":false,"given":"Jin-Sung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in lateronset spinal muscular atrophy long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","article-title":"Ambulatory function in spinal muscular atrophy: age-related patterns of progression","volume":"13","author":"Montes","year":"2018","journal-title":"PLoS One"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"R8-20250504","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418803246","article-title":"Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy","volume":"11","author":"Stolte","year":"2018","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:25:00Z","timestamp":1746339900000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024236"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024236","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"2020-09-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}